Effects of the NMDA/glycine receptor antagonist, L-701,324, on morphine- and cocaine-induced place preference

Polish Journal of Pharmacology

Volumn 51, Issue 4, 1999, Pages 323-330

  Kotlińska, Jolanta ^a   Biała, Grazyna ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Cocaine; Conditioned place preference paradigm; L 701,324; Morphine

Indexed keywords

7 CHLORO 4 HYDROXY 3 (3 PHENOXYPHENYL) 2 QUINOLONE; COCAINE; GLYCINE RECEPTOR ANTAGONIST; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PLACE PREFERENCE; RAT;

ANALGESICS, OPIOID; ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; COCAINE; CONDITIONING, OPERANT; DOPAMINE UPTAKE INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MORPHINE; QUINOLONES; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0032834386     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Anthony E. W., Nevis M. E.: Anxiolytic-like effects of N-methyl-D-aspartate-associated glycine receptor ligands in the rat potentiated startle test. Eur. J. Pharmacol., 1993, 250, 317-324.
2. Balster R. L.: The behavioral pharmacology of phencyclidine. In: Psychopharmacology. The 3rd Generation of Progress. Ed.: Meltzer H. Y., Raven Press, New York, 1987, 1573-1580.
3. Bespalov A., Dumpis M., Piotrovsky L., Zvartau E.: Excitatory amino acid receptor antagonist kynurenic acid attenuates rewarding potential of morphine. Eur. J. Pharmacol., 1994, 264, 233-239.
4. Bozarth M. A.: Conditioned place preference: a parametric analysis using system heroin injection. In: Methods of Assessing the Reinforcing Properties of Abused Drugs. Ed.: Bozarth M. A., Springer Verlag, New York, 1987, 241-273.
5. Bristow L. J., Hutson P. H., Kulagowski J. J., Leeson P. D., Matheson S., Murray F., Rathbone D., Saywell K. L., Thorn L., Watt A. P., Tricklebank M. D.: Anticonvulsant and behavioral profile of L-701,324, a potent, orally active antagonist at the glycine modulatory site on the N-methyl-D-aspartate receptor complex. J. Pharmacol. Exp. Ther., 1996, 279, 492-501.
6. Cabib S., Castellano C., Cestari V., Filibeck U., Puglisi-Allegra S.: D1 and D2 receptor antagonists differently affect cocaine-induced locomotor hyperactivity in the mouse. Psychopharmacology, 1991, 105, 335-339.
7. Carter A. J.: Antagonists of the NMDA receptor-channel complex and motor coordination. Life Sci., 1995, 57, 917-929.
8. Cervo L., Samanin R.: Effects of dopaminergic and glutamatergic receptor antagonists on the acquisition and expression of cocaine conditioning place preference. Brain Res., 1995, 673, 242-250.
9. Clineschmidt B. V., Martin G. E., Bunting P. R.: Central sympathomimetic activity of (±)-5-methyl-10,11-dihydro-5H-dibenzo-[a,d]cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Develop. Res., 1982, 2, 134-145.
10. Corbett D.: Possible abuse potential of the NMDA antagonist MK-801. Behav. Brain Res., 1989, 34, 239-246.
11. Del Pozo E., Barrios M., Baeyens J. M.: The NMDA receptor antagonist dizocilpine (MK-801) stereoselectively inhibits morphine-induced place preference conditioning in mice. Psychopharmacology, 1996, 125, 209-213.
12. Faiman C. P., Vin E. Skolnick P., Trullas R.: Different effects of compounds that act at strychnine-insensitive glycine receptors in a punishment procedure. J. Pharmacol. Exp. Ther., 1994, 270, 528-533.
13. Gilbert D., Cooper S. J.: Beta-phenylethylamine-, d-amphetamine-and l-amphetamine-induced place preference conditioning in rats. Eur. J. Pharmacol., 1983, 95, 311-314.
14. González P., Cabello P., Germany A., Norris B., Contreras E.: Decrease of tolerance to, and physical dependence on morphine by glutamate receptor antagonists. Eur. J. Pharmacol., 1997, 332, 257-262.
15. Heikkila R. E., Cabbot F. S., Manzino L., Duvoisin R. C.: Rotational behavior induced by cocaine analogs in rats with unilateral 6-hydroxydopamine lesions of the substantia nigra: dependence upon dopamine uptake inhibition. J. Pharmacol. Exp. Ther., 1979, 211, 189-194.
16. Herberg L. J., Rose I. C.: The effect of MK-801 and other antagonists of NMDA-type glutamate receptors on brain stimulation reward. Psychopharmacology, 1989, 99, 87-90.
17. Hutson P. H., Barton Ch. L.: L-701,324, a glycine/ NMDA receptor antagonist, blocks the increase of cortical dopamine metabolism by stress and DMCM. Eur. J. Pharmacol., 1997, 326, 127-132.
18. Johnson S. W., North R. A.: Opioids excite dopamine neurons by hyperpolarization of local interneurons. J. Neurosci., 1992, 12, 483-488.
19. Kim H. S., Jang C. G., Park W. K.: Inhibition by MK-801 of morphine-induced conditioned place preference and postsynaptic dopamine receptor supersensitivity in mice. Pharmacol. Biochem. Behav., 1996, 55, 11-17.
20. Kim H. S., Park W. K., Jang C. G., Oh S.: Inhibition by MK-801 of cocaine-induced sensitization, conditioned place preference, and dopamine-receptor supersensitivity in mice. Brain Res. Bull., 1996, 40, 201-207.
21. Kotlińska J., Liljequist S.: Oral administration of glycine and polyamine receptor antagonists blocks ethanol withdrawal seizures. Psychopharmacology, 1996, 127, 238-244.
22. Kotlińska J., Liljequist S.: A characterization of anxiolytic-like actions induced by the novel NMDA/glycine site antagonist, L-701,324. Psychopharmacology, 1998, 135, 175-181.
23. Layer R. T., Kaddis F. G., Wallace L. J.: The NMDA receptor antagonist MK-801 elicits conditioned place preference in rats. Pharmacol. Biochem. Behav., 1993, 44, 245-247.
24. Leeson P. D. Iversen L. L.: The glycine site on the NMDA receptor: Structure-activity relationships and therapeutic potential. J. Med. Chem., 1994, 37, 4053-4067.
25. Löscher W., Annies R., Hönack D.: The N-methyl-D-aspartate receptor antagonist MK-801 induces increase in dopamine and serotonin metabolism in several brain regions of rats. Neurosci. Lett., 1991, 128, 191-194.
26. Lutfy K., Shen K. Z., Kwon I. S., Cai S. X., Woodward R. M., Kean J. F. W., Weber E.: Blockade of morphine tolerance by ACEA-1328, a novel NMDA receptor/ glycine site antagonist. Eur. J. Pharmacol., 1995, 273, 187-189.
27. Matsumoto R. R., Brackett R. L., Kanthasamy A. G.: Novel NMDA/glycine site antagonists attenuate cocaine-induced behavioral toxicity. Eur. J. Pharmacol., 1997, 338, 233-242.
28. Meldrum B.: Possible therapeutic application of antagonists of excitatory amino acid neurotransmitters. Clin. Sci., 1985, 68, 113-123.
29. Moore K. E., Chiueh C. C., Zelders G.: Release of neurotransmitters from the brain in vivo by amphetamine, methylphenidate and cocaine. In: Cocaine and Other Stimulants. Eds. Ellinwood E. H., Kilbey M. M., Plenum, New York, 1977, 143-160.
30. Morency M. A., Beninger R. J.: Dopaminergic substrates of cocaine-induced place conditioning. Brain Res., 1987, 399, 33-41.
31. Olney J.: Excitatory amino acids and neuropsychiatric disorders. Biol. Psychiat., 1989, 26, 505-525.
32. Papp M., Moryl E., Maccecchini M. L.: Differential effects of agents acting at various sites of the NMDA receptor complex in a place preference conditioning model. Eur. J. Pharmacol., 1996, 317, 191-196.
33. Paul I. A., Nowak G., Layer R. T., Popik P., Skolnick P.: Adaptation of the N-methyl-D-aspartate receptor complex following antidepressant treatments. J. Pharmacol. Exp. Ther., 1994, 296, 95-102.
34. Popik P., Danysz W.: Inhibition of reinforcing effects of morphine and motivational aspects of naloxone-precipitated opioid withdrawal by NMDA receptor antagonist, memantine. J. Pharmacol. Exp. Ther., 1997, 280, 854-856.
35. Popik P., Mamczarz J., Fraczek M., Widła M., Hesselink M., Danysz W.: Inhibition of reinforcing effects of morphine and naloxone-precipitated opioid withdrawal by novel glycine site and uncompetitive NMDA receptor antagonists. Neuropharmacology, 1998, 37, 1033-1042.
36. Priestley T., Laughton P., Macaulay A. J., Hill R. G., Kemp J. A.: Electrophysiological characterization of the antagonist properties of two novel NMDA receptor glycine site antagonists, L-695,902 and L-701,324, Neuropharmacology, 1996, 11, 1573-1581.
37. Rao T. S., Kim H. S., Lehmann J., Martin L. L.: Interactions of phencyclidine receptor agonist MK-801 with dopaminergic system: regional studies in the rat. J. Neurochem., 1990, 54, 1157-1162.
38. Reid L. D., Marglin S. H., Mattie M. E., Hubbell C. L.: Measuring morphine's capacity to establish a place preference. Pharmacol. Biochem. Behav., 1989, 33, 746-775.
39. Roberts P. J., Porter R. H. P.: Characterization and modulation of binding to the glutamate receptor. In: CNS Neurotransmitters and Neuromodulators: Glutamate. Ed.: Stone T. W., CRS Press, Boca Raton, 1995, 66-82.
40. Rogawski M. A.: Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol. Sci., 1993, 14, 325-331.
41. Ross S. F., Renyi A. L.: Inhibition of the uptake of tritiated catecholamines by antidepressants and related agents. Eur. J. Pharmacol., 1967, 2, 181-186.
42. Rossetti Z. L., Hmaidan Y., Gessa G. L.: Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. Eur. J. Pharmacol., 1992, 221, 227-234.
43. Rundfeldt C., Wlaz P., Löscher W.: Anticonvulsant activity of antagonists and partial agonists for the NMDA receptor associated glycine site in the kindling model of epilepsy. Brain Res., 1994, 653, 125-130.
44. Scatton B.: The NMDA receptor complex. Fundam. Clin. Pharmacol., 1993, 7, 389-400.
45. Suzuki T., Funada M., Narita M., Misawa M., Nagase H.: Morphine-induced place preference in the CXBK mouse: characteristic of μ opioid receptor subtypes. Brain Res., 1993, 602, 45-52.
46. Trujillo K. A., Akil H.: Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science, 1991, 251, 85-87.
47. Tzschentke T. M., Schmidt W. J.: N-methyl-D-aspartic acid receptor antagonists block morphine-induced conditioned place preference in rats. Neurosci. Lett., 1995, 193, 37-40.
48. Tzschentke T. M., Schmidt W. J.: Interactions of MK-801 and GYKI 52466 with morphine and amphetamine in place preference conditioning and behavioural sensitization. Behav. Brain Res., 1997, 84, 99-107.
49. Tzschentke T. M., Schmidt W. J.: Blockade of morphine-and amphetamine-induced conditioned place preference in the rat by riluzole. Neurosci. Lett., 1998, 242, 114-116.
50. Van der Kooy D.: Place conditioning: a simple and effective method for assessing the motivatonal properties of drugs. In: Methods of Assessing the Reinforcing Properties of Abuse Drugs. Ed.: Bozarth M. A., Springer Verlag, New York, 1987, 229-240.
51. Willetts J., Balster R. L., Leander J. D.: The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol. Sci., 1990, 11, 423-428.
52. Witkin J. M.: Role of NMDA receptor in behavioral effects of drugs. In: CNS Neurotransmitters and Neuro-modulators: Glutamate. Ed.: T.W. Stone, CRS Press, Boca Raton, 1995, 323-350.